Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 36 | 2024 | 2894 | 4.010 |
Why?
|
Carcinoma, Squamous Cell | 21 | 2024 | 4021 | 1.980 |
Why?
|
Immunotherapy | 19 | 2024 | 4642 | 1.950 |
Why?
|
Carcinoma, Adenoid Cystic | 5 | 2021 | 262 | 1.890 |
Why?
|
Oropharyngeal Neoplasms | 9 | 2023 | 491 | 1.590 |
Why?
|
Radiotherapy | 7 | 2023 | 1500 | 1.500 |
Why?
|
Radiotherapy, Intensity-Modulated | 8 | 2022 | 801 | 1.350 |
Why?
|
Neoplasms | 23 | 2024 | 22142 | 1.240 |
Why?
|
Papillomavirus Infections | 9 | 2023 | 1616 | 1.080 |
Why?
|
Combined Modality Therapy | 17 | 2024 | 8519 | 0.960 |
Why?
|
Neoplasm Recurrence, Local | 21 | 2024 | 9278 | 0.950 |
Why?
|
Carcinoma, Merkel Cell | 4 | 2024 | 328 | 0.850 |
Why?
|
Mouth Neoplasms | 4 | 2022 | 596 | 0.780 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 5321 | 0.780 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 11733 | 0.750 |
Why?
|
Neoplasm Metastasis | 11 | 2022 | 4909 | 0.650 |
Why?
|
Radioimmunotherapy | 1 | 2019 | 90 | 0.630 |
Why?
|
Melanoma | 9 | 2021 | 5694 | 0.620 |
Why?
|
Radiation Tolerance | 2 | 2023 | 478 | 0.620 |
Why?
|
Medical Futility | 1 | 2019 | 136 | 0.600 |
Why?
|
Skin Neoplasms | 9 | 2024 | 5809 | 0.600 |
Why?
|
Neck | 1 | 2022 | 734 | 0.590 |
Why?
|
Radiotherapy Dosage | 9 | 2022 | 2897 | 0.590 |
Why?
|
Neoadjuvant Therapy | 7 | 2023 | 2827 | 0.590 |
Why?
|
Peer Review, Health Care | 1 | 2017 | 73 | 0.550 |
Why?
|
Head | 1 | 2022 | 922 | 0.540 |
Why?
|
Radiation Oncology | 3 | 2017 | 563 | 0.540 |
Why?
|
Lymphopenia | 1 | 2018 | 282 | 0.530 |
Why?
|
Salivary Gland Neoplasms | 3 | 2020 | 304 | 0.510 |
Why?
|
Lung Neoplasms | 7 | 2024 | 13386 | 0.510 |
Why?
|
Papillomaviridae | 8 | 2022 | 1120 | 0.490 |
Why?
|
Immunomodulation | 1 | 2019 | 548 | 0.480 |
Why?
|
Antineoplastic Agents | 10 | 2024 | 13632 | 0.480 |
Why?
|
Tumor Microenvironment | 7 | 2023 | 3875 | 0.470 |
Why?
|
Carcinoma, Basal Cell | 3 | 2024 | 557 | 0.450 |
Why?
|
Humans | 116 | 2024 | 761222 | 0.450 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2015 | 349 | 0.440 |
Why?
|
Cancer Vaccines | 2 | 2011 | 1038 | 0.430 |
Why?
|
Immunocompromised Host | 1 | 2019 | 858 | 0.430 |
Why?
|
Cookbooks as Topic | 1 | 2012 | 1 | 0.430 |
Why?
|
Retrospective Studies | 33 | 2024 | 80675 | 0.430 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 5 | 2022 | 1655 | 0.420 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 1089 | 0.410 |
Why?
|
Saliva | 1 | 2017 | 828 | 0.400 |
Why?
|
Radiation Injuries | 4 | 2021 | 1191 | 0.400 |
Why?
|
Antibodies, Monoclonal | 2 | 2022 | 9187 | 0.400 |
Why?
|
Angiogenesis Inhibitors | 2 | 2012 | 2047 | 0.390 |
Why?
|
Neoplasm Staging | 13 | 2024 | 11119 | 0.380 |
Why?
|
Endoribonucleases | 1 | 2013 | 227 | 0.370 |
Why?
|
Brain Neoplasms | 7 | 2021 | 9025 | 0.370 |
Why?
|
Immunotherapy, Active | 1 | 2010 | 58 | 0.360 |
Why?
|
Middle Aged | 51 | 2024 | 220858 | 0.360 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2020 | 1784 | 0.360 |
Why?
|
Molecular Targeted Therapy | 2 | 2021 | 2813 | 0.360 |
Why?
|
Aged | 44 | 2024 | 169292 | 0.350 |
Why?
|
Carcinoma | 2 | 2023 | 2330 | 0.330 |
Why?
|
Neoplasms, Unknown Primary | 2 | 2022 | 101 | 0.330 |
Why?
|
Antibodies, Neoplasm | 1 | 2010 | 282 | 0.330 |
Why?
|
Radiosurgery | 4 | 2020 | 1339 | 0.320 |
Why?
|
Palliative Care | 3 | 2020 | 3599 | 0.320 |
Why?
|
Papillomavirus Vaccines | 1 | 2015 | 496 | 0.310 |
Why?
|
Male | 56 | 2024 | 360703 | 0.300 |
Why?
|
Immunophenotyping | 3 | 2018 | 1867 | 0.300 |
Why?
|
Food | 1 | 2012 | 768 | 0.290 |
Why?
|
Aged, 80 and over | 25 | 2024 | 58952 | 0.290 |
Why?
|
Survival Analysis | 9 | 2021 | 10088 | 0.290 |
Why?
|
Appointments and Schedules | 1 | 2011 | 442 | 0.290 |
Why?
|
Pneumonia | 1 | 2019 | 2142 | 0.280 |
Why?
|
Patient Selection | 2 | 2021 | 4246 | 0.280 |
Why?
|
Neoplasm Proteins | 2 | 2018 | 3594 | 0.280 |
Why?
|
Female | 52 | 2024 | 392552 | 0.270 |
Why?
|
Stomach Neoplasms | 1 | 2016 | 1457 | 0.260 |
Why?
|
Pyrroles | 1 | 2012 | 1124 | 0.260 |
Why?
|
Antibodies, Viral | 1 | 2017 | 3149 | 0.250 |
Why?
|
Kaplan-Meier Estimate | 6 | 2020 | 6486 | 0.250 |
Why?
|
Carcinoma, Renal Cell | 2 | 2018 | 3163 | 0.250 |
Why?
|
Tumor Burden | 2 | 2021 | 1892 | 0.230 |
Why?
|
Neovascularization, Pathologic | 2 | 2011 | 2636 | 0.230 |
Why?
|
Colorectal Neoplasms | 2 | 2021 | 6919 | 0.230 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12474 | 0.220 |
Why?
|
Hodgkin Disease | 1 | 2011 | 1379 | 0.220 |
Why?
|
Indoles | 1 | 2012 | 1830 | 0.220 |
Why?
|
Neoplasms, Second Primary | 1 | 2011 | 1052 | 0.220 |
Why?
|
Research Design | 1 | 2019 | 6180 | 0.220 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2731 | 0.220 |
Why?
|
Radiation Dosage | 2 | 2022 | 1962 | 0.210 |
Why?
|
Organs at Risk | 2 | 2022 | 359 | 0.210 |
Why?
|
Pregnancy Proteins | 1 | 2004 | 223 | 0.210 |
Why?
|
Prognosis | 12 | 2024 | 29688 | 0.200 |
Why?
|
Dermatitis | 2 | 2017 | 202 | 0.200 |
Why?
|
Prostatic Neoplasms | 5 | 2020 | 11101 | 0.190 |
Why?
|
Gadolinium | 2 | 2024 | 961 | 0.190 |
Why?
|
CD8-Positive T-Lymphocytes | 5 | 2023 | 4574 | 0.190 |
Why?
|
Gene Expression Profiling | 4 | 2021 | 9417 | 0.190 |
Why?
|
Nasolacrimal Duct | 1 | 2022 | 79 | 0.190 |
Why?
|
Immune System | 2 | 2018 | 792 | 0.190 |
Why?
|
Kidney Neoplasms | 2 | 2018 | 4251 | 0.180 |
Why?
|
Treatment Outcome | 16 | 2024 | 64681 | 0.180 |
Why?
|
Parotid Gland | 1 | 2022 | 176 | 0.180 |
Why?
|
Disease-Free Survival | 7 | 2021 | 6819 | 0.180 |
Why?
|
Granuloma, Plasma Cell | 1 | 2021 | 80 | 0.180 |
Why?
|
Cisplatin | 3 | 2024 | 1652 | 0.180 |
Why?
|
Immunologic Factors | 2 | 2021 | 1589 | 0.180 |
Why?
|
Prostatectomy | 3 | 2014 | 1825 | 0.180 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 8002 | 0.170 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2012 | 3366 | 0.170 |
Why?
|
Antibody Formation | 2 | 2016 | 1391 | 0.160 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2021 | 290 | 0.160 |
Why?
|
Cytokines | 4 | 2019 | 7386 | 0.160 |
Why?
|
Adult | 29 | 2024 | 221120 | 0.160 |
Why?
|
Drugs, Investigational | 1 | 2021 | 212 | 0.160 |
Why?
|
Thyroid Neoplasms | 1 | 2012 | 2330 | 0.160 |
Why?
|
Nucleic Acid Denaturation | 1 | 2018 | 110 | 0.150 |
Why?
|
Tomography, X-Ray Computed | 6 | 2023 | 20588 | 0.150 |
Why?
|
Sarcopenia | 1 | 2023 | 370 | 0.150 |
Why?
|
Anti-Infective Agents, Local | 1 | 2020 | 247 | 0.150 |
Why?
|
Laryngeal Neoplasms | 1 | 2022 | 514 | 0.150 |
Why?
|
Survival Rate | 4 | 2018 | 12728 | 0.150 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2024 | 5301 | 0.150 |
Why?
|
Positron-Emission Tomography | 2 | 2022 | 6586 | 0.150 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2010 | 3493 | 0.150 |
Why?
|
Radiation Protection | 1 | 2021 | 426 | 0.140 |
Why?
|
Stomatitis | 1 | 2020 | 271 | 0.140 |
Why?
|
Mouth | 1 | 2020 | 380 | 0.140 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 246 | 0.140 |
Why?
|
Larynx | 1 | 2022 | 492 | 0.140 |
Why?
|
Quality Assurance, Health Care | 2 | 2017 | 2164 | 0.140 |
Why?
|
Polymerase Chain Reaction | 3 | 2024 | 6067 | 0.140 |
Why?
|
Phantoms, Imaging | 2 | 2022 | 2513 | 0.140 |
Why?
|
Osteoradionecrosis | 1 | 2017 | 51 | 0.140 |
Why?
|
Financial Management | 1 | 2018 | 160 | 0.140 |
Why?
|
Epirubicin | 1 | 2016 | 81 | 0.130 |
Why?
|
Lymphocyte Count | 1 | 2018 | 781 | 0.130 |
Why?
|
Hyperbaric Oxygenation | 1 | 2017 | 165 | 0.130 |
Why?
|
Prospective Studies | 8 | 2021 | 54437 | 0.120 |
Why?
|
Gastrointestinal Tract | 1 | 2021 | 834 | 0.120 |
Why?
|
Mucositis | 2 | 2019 | 108 | 0.120 |
Why?
|
Tooth Diseases | 1 | 2015 | 73 | 0.120 |
Why?
|
Signal Transduction | 3 | 2015 | 23419 | 0.120 |
Why?
|
Chemokines | 2 | 2018 | 956 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2017 | 390 | 0.120 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12052 | 0.120 |
Why?
|
Nanoparticles | 2 | 2024 | 1959 | 0.120 |
Why?
|
Ecosystem | 1 | 2018 | 489 | 0.110 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2022 | 2024 | 0.110 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1057 | 0.110 |
Why?
|
Drug Carriers | 1 | 2018 | 705 | 0.110 |
Why?
|
Creatinine | 1 | 2019 | 1897 | 0.110 |
Why?
|
Breast Neoplasms | 3 | 2020 | 20982 | 0.110 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39127 | 0.100 |
Why?
|
Lymph Nodes | 3 | 2023 | 3461 | 0.100 |
Why?
|
SEER Program | 4 | 2020 | 1453 | 0.100 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1302 | 0.100 |
Why?
|
Information Dissemination | 1 | 2021 | 1129 | 0.100 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1084 | 0.100 |
Why?
|
Killer Cells, Natural | 2 | 2018 | 2194 | 0.100 |
Why?
|
Interferon-gamma | 1 | 2020 | 3155 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3512 | 0.100 |
Why?
|
Computational Biology | 1 | 2004 | 3499 | 0.100 |
Why?
|
Drug Therapy | 1 | 2015 | 503 | 0.100 |
Why?
|
Endothelium, Vascular | 1 | 2004 | 4420 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 899 | 0.090 |
Why?
|
Medical Oncology | 1 | 2023 | 2320 | 0.090 |
Why?
|
Gastrectomy | 1 | 2016 | 672 | 0.090 |
Why?
|
Lymphatic Metastasis | 2 | 2016 | 2913 | 0.090 |
Why?
|
Interferons | 1 | 2015 | 702 | 0.090 |
Why?
|
International Cooperation | 1 | 2017 | 1423 | 0.090 |
Why?
|
Neoplasm, Residual | 1 | 2016 | 1008 | 0.090 |
Why?
|
Transcription, Genetic | 2 | 2004 | 7571 | 0.090 |
Why?
|
Xerostomia | 1 | 2010 | 94 | 0.090 |
Why?
|
Angiopoietin-1 | 1 | 2010 | 122 | 0.090 |
Why?
|
Immunity, Cellular | 1 | 2016 | 1553 | 0.090 |
Why?
|
Receptor, TIE-2 | 1 | 2010 | 176 | 0.090 |
Why?
|
Inflammation Mediators | 1 | 2019 | 1885 | 0.090 |
Why?
|
Carcinoma, Mucoepidermoid | 1 | 2010 | 89 | 0.090 |
Why?
|
Angiopoietin-2 | 1 | 2010 | 173 | 0.080 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2022 | 628 | 0.080 |
Why?
|
Esophagitis | 1 | 2010 | 165 | 0.080 |
Why?
|
BRCA1 Protein | 1 | 2016 | 1149 | 0.080 |
Why?
|
Young Adult | 9 | 2021 | 59222 | 0.080 |
Why?
|
T-Lymphocytes | 2 | 2018 | 10203 | 0.080 |
Why?
|
Androgen Antagonists | 2 | 2020 | 1408 | 0.080 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2024 | 858 | 0.080 |
Why?
|
Leadership | 1 | 2018 | 1385 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2024 | 10218 | 0.080 |
Why?
|
Cytoskeletal Proteins | 2 | 2005 | 1334 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 3245 | 0.080 |
Why?
|
Radiopharmaceuticals | 2 | 2022 | 2684 | 0.080 |
Why?
|
Colitis | 1 | 2017 | 1234 | 0.080 |
Why?
|
Apoptosis | 1 | 2024 | 9478 | 0.080 |
Why?
|
Gene Library | 1 | 2010 | 1054 | 0.070 |
Why?
|
Recurrence | 1 | 2020 | 8457 | 0.070 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1746 | 0.070 |
Why?
|
Risk Factors | 6 | 2023 | 74241 | 0.070 |
Why?
|
Carboplatin | 1 | 2010 | 793 | 0.070 |
Why?
|
Melanoma, Experimental | 1 | 2010 | 561 | 0.070 |
Why?
|
Hematologic Neoplasms | 1 | 2019 | 1895 | 0.070 |
Why?
|
Cohort Studies | 6 | 2024 | 41496 | 0.070 |
Why?
|
Animals | 10 | 2022 | 168089 | 0.070 |
Why?
|
Incidental Findings | 1 | 2011 | 698 | 0.070 |
Why?
|
Mucous Membrane | 2 | 2021 | 659 | 0.070 |
Why?
|
Immunity, Humoral | 1 | 2010 | 598 | 0.070 |
Why?
|
Mastectomy, Segmental | 1 | 2011 | 955 | 0.070 |
Why?
|
beta Catenin | 3 | 2006 | 1042 | 0.070 |
Why?
|
Time Factors | 3 | 2021 | 39957 | 0.060 |
Why?
|
Glioblastoma | 1 | 2021 | 3482 | 0.060 |
Why?
|
Neutrophils | 1 | 2018 | 3763 | 0.060 |
Why?
|
Developing Countries | 1 | 2017 | 2863 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2023 | 20118 | 0.060 |
Why?
|
Prostate | 1 | 2013 | 1772 | 0.060 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2013 | 1520 | 0.060 |
Why?
|
Trans-Activators | 2 | 2005 | 2846 | 0.060 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2006 | 412 | 0.060 |
Why?
|
Inflammation | 2 | 2015 | 10759 | 0.060 |
Why?
|
Genomics | 1 | 2020 | 5829 | 0.060 |
Why?
|
Patient Preference | 1 | 2011 | 927 | 0.060 |
Why?
|
Risk Assessment | 3 | 2021 | 24022 | 0.060 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2024 | 198 | 0.050 |
Why?
|
Neoplasm Invasiveness | 1 | 2011 | 3590 | 0.050 |
Why?
|
Umbilical Veins | 1 | 2004 | 423 | 0.050 |
Why?
|
Philadelphia | 1 | 2023 | 267 | 0.050 |
Why?
|
Paclitaxel | 1 | 2010 | 1730 | 0.050 |
Why?
|
X-Rays | 1 | 2024 | 307 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2013 | 3210 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 2691 | 0.050 |
Why?
|
Capillary Permeability | 1 | 2006 | 773 | 0.050 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11067 | 0.050 |
Why?
|
Logistic Models | 1 | 2017 | 13249 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2018 | 8531 | 0.050 |
Why?
|
Genotype | 2 | 2016 | 12985 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7407 | 0.050 |
Why?
|
Culture Media | 1 | 2004 | 894 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2020 | 4851 | 0.050 |
Why?
|
Particle Accelerators | 1 | 2022 | 174 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3821 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10707 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2022 | 36415 | 0.040 |
Why?
|
Genetic Variation | 1 | 2016 | 6567 | 0.040 |
Why?
|
Mice | 5 | 2022 | 81330 | 0.040 |
Why?
|
Endothelium | 1 | 2003 | 763 | 0.040 |
Why?
|
Antigens, CD | 1 | 2010 | 4009 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2024 | 2263 | 0.040 |
Why?
|
Receptor, erbB-2 | 2 | 2020 | 2553 | 0.040 |
Why?
|
Bandages | 1 | 2020 | 269 | 0.040 |
Why?
|
Nasopharynx | 1 | 2021 | 400 | 0.040 |
Why?
|
Hypokalemia | 1 | 2019 | 153 | 0.040 |
Why?
|
Algorithms | 2 | 2023 | 14025 | 0.040 |
Why?
|
Mohs Surgery | 1 | 2020 | 222 | 0.040 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2018 | 359 | 0.040 |
Why?
|
Disease Progression | 3 | 2020 | 13511 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2016 | 15920 | 0.040 |
Why?
|
Jaw | 1 | 2017 | 92 | 0.030 |
Why?
|
Obesity | 1 | 2019 | 12940 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 883 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 53 | 0.030 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2018 | 880 | 0.030 |
Why?
|
Frameshift Mutation | 1 | 2018 | 392 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2019 | 422 | 0.030 |
Why?
|
Necrosis | 1 | 2020 | 1610 | 0.030 |
Why?
|
Brain | 1 | 2022 | 27094 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2012 | 7400 | 0.030 |
Why?
|
Receptors, Progesterone | 1 | 2020 | 1129 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2217 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1264 | 0.030 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 1 | 2018 | 324 | 0.030 |
Why?
|
Postoperative Period | 1 | 2019 | 1818 | 0.030 |
Why?
|
Cyclin D1 | 1 | 2016 | 451 | 0.030 |
Why?
|
United States | 3 | 2024 | 72341 | 0.030 |
Why?
|
Workflow | 1 | 2018 | 850 | 0.030 |
Why?
|
Endothelial Cells | 1 | 2006 | 3552 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2010 | 6341 | 0.030 |
Why?
|
Receptor, Notch1 | 1 | 2016 | 497 | 0.030 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 697 | 0.030 |
Why?
|
Diarrhea | 1 | 2019 | 1316 | 0.030 |
Why?
|
HIV Infections | 1 | 2019 | 17348 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2018 | 5871 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2006 | 18927 | 0.020 |
Why?
|
Receptors, Estrogen | 1 | 2020 | 2208 | 0.020 |
Why?
|
Surgical Wound Infection | 1 | 2020 | 1530 | 0.020 |
Why?
|
Incidence | 2 | 2020 | 21366 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2018 | 1838 | 0.020 |
Why?
|
Swine | 1 | 2021 | 5909 | 0.020 |
Why?
|
Breast | 1 | 2020 | 1964 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4342 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2021 | 8164 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2022 | 3671 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2024 | 12341 | 0.020 |
Why?
|
Wound Healing | 1 | 2020 | 2800 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4107 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 2041 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7189 | 0.020 |
Why?
|
Proteins | 1 | 2004 | 5993 | 0.020 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2054 | 0.020 |
Why?
|
Contrast Media | 1 | 2021 | 5311 | 0.020 |
Why?
|
Documentation | 1 | 2015 | 900 | 0.020 |
Why?
|
Blotting, Western | 2 | 2006 | 5032 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2018 | 5478 | 0.020 |
Why?
|
Decision Making | 1 | 2021 | 3931 | 0.020 |
Why?
|
Histamine Agents | 1 | 2006 | 3 | 0.020 |
Why?
|
Receptors, Histamine | 1 | 2006 | 23 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2018 | 2223 | 0.020 |
Why?
|
DNA Damage | 1 | 2016 | 2443 | 0.020 |
Why?
|
Biopsy | 1 | 2018 | 6781 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2004 | 11855 | 0.020 |
Why?
|
gamma Catenin | 1 | 2005 | 44 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4373 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2915 | 0.020 |
Why?
|
Desmoplakins | 1 | 2005 | 61 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10553 | 0.020 |
Why?
|
Phosphoserine | 1 | 2005 | 203 | 0.010 |
Why?
|
Rats | 1 | 2021 | 23705 | 0.010 |
Why?
|
Alleles | 1 | 2016 | 6857 | 0.010 |
Why?
|
Base Sequence | 1 | 2016 | 12404 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2317 | 0.010 |
Why?
|
Histamine | 1 | 2006 | 499 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2022 | 11512 | 0.010 |
Why?
|
Quality Improvement | 1 | 2019 | 3808 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3634 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2003 | 812 | 0.010 |
Why?
|
Quality of Life | 1 | 2024 | 13367 | 0.010 |
Why?
|
Registries | 1 | 2018 | 8246 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 2006 | 2468 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18222 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2015 | 3534 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26072 | 0.010 |
Why?
|
Body Mass Index | 1 | 2019 | 12952 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2005 | 1487 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 12976 | 0.010 |
Why?
|
Exons | 1 | 2005 | 2380 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15308 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2016 | 9567 | 0.010 |
Why?
|
Cytoplasm | 1 | 2003 | 1498 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2006 | 2455 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2015 | 4822 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2006 | 2864 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2003 | 3091 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2003 | 2635 | 0.010 |
Why?
|
Actins | 1 | 2003 | 2046 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 4451 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2005 | 6504 | 0.010 |
Why?
|
Phosphorylation | 1 | 2006 | 8300 | 0.010 |
Why?
|
Transfection | 1 | 2003 | 5748 | 0.010 |
Why?
|
Mutation | 1 | 2018 | 30004 | 0.010 |
Why?
|
Protein Binding | 1 | 2005 | 9297 | 0.010 |
Why?
|
Cell Line | 1 | 2005 | 15545 | 0.010 |
Why?
|
Models, Biological | 1 | 2006 | 9458 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2003 | 14392 | 0.000 |
Why?
|
Adolescent | 1 | 2015 | 88300 | 0.000 |
Why?
|
Lung | 1 | 2003 | 9979 | 0.000 |
Why?
|